Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Blood (2021) 138 (14): 1237–1248.

https://doi.org/10.1182/blood.2020009064

Published: 2021

Includes: Supplemental data

Journal Articles

BRAF V600E vs cell of origin: what governs LCH?

Kenneth L. McClain, Rikhia Chakraborty

Blood (2021) 138 (14): 1203–1204.

https://doi.org/10.1182/blood.2021012907

Published: 2021

Journal Articles

Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

Amel Sengal, Jessica Velazquez, Meryl Hahne, Thomas M. Burke, Harshal Abhyankar, Robert Reyes, Walter Olea, Brooks Scull, Olive S. Eckstein, Camille Bigenwald, Catherine M. Bollard, Wendong Yu, Miriam Merad, Kenneth L. McClain, Carl E. Allen, Rikhia Chakraborty

Blood (2021) 137 (13): 1777–1791.

https://doi.org/10.1182/blood.2020005867

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Francesco Pegoraro, Valerio Maniscalco, Francesco Peyronel, Pieter J. Westenend, Tadek R. Hendriksz, Rosa M. Roperto, Alessandro A. Palumbo, Elena Sieni, Paola Romagnani, Eric F. H. van Bommel, Augusto Vaglio

Blood (2020) 135 (22): 1994–1997.

https://doi.org/10.1182/blood.2019004478

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Langerhans cell histiocytosis

Carlos Rodriguez-Galindo, Carl E. Allen

Blood (2020) 135 (16): 1319–1331.

https://doi.org/10.1182/blood.2019000934

Published: 2020

Includes: Supplemental data

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Ko Kudo, MD, Rika Kanezaki, PhD, Akie Kobayashi, MD, Tomohiko Sato, MD PhD, Takuya Kamio, MD PhD, Shinya Sasaki, MD PhD, Imamura Masaru, MD PhD, Chihaya Imai, MD PhD, Masahiro Irie, MD PhD, Yoji Sasahara, MD PhD, Kumiko Ando, MD, Harumi Kakuda, MD PhD, Takehiko Doi, MD PhD, Hiroshi Kawaguchi, MD PhD, Kazuko Kudo, MD PhD, Hirokazu Kanegane, MD PhD, Kiminori Terui, MD PhD, Tsutomu Toki, PhD, Etsuro Ito, MD PhD

Blood (2019) 134 (Supplement_1): 3588.

https://doi.org/10.1182/blood-2019-127536

Published: 2019

Journal Articles

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Johannes M. Waldschmidt, MD, Jake A. Kloeber, Tushara Vijaykumar, Antonis Kokkalis, PhD MSc, Praveen Anand, PhD, Sayalee Potdar, Julia Frede, PhD MPhil, Monica S. Nair, Valeriya Dimitrova, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Andrew J. Yee, MD, Noopur S. Raje, MD, Birgit Knoechel, MD PhD, Jens G. Lohr, MD PhD

Blood (2019) 134 (Supplement_1): 316.

https://doi.org/10.1182/blood-2019-130313

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Journal Articles

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

Mariana Bastos-Oreiro, MD PhD, Julia Suárez González, Natalia Carolina Carrión, Cristina Andres, Solsireey Moreno, Diego Carbonell, Mr, María Chicano Lavilla, PhD, Gillen Oarbeascoa, MD, Francisco Diaz Crespo, Javier Menarguez, MD PhD, José Luis Díez-Martín, MD PhD, Ismael Buño, PhD, Carolina Martínez-Laperche

Blood (2019) 134 (Supplement_1): 5216.

https://doi.org/10.1182/blood-2019-129868

Published: 2019

Journal Articles

Creating and Testing a CD207+ Langerhans Cell Histiocytosis-like Cell Line

Jessica Velazquez, BS, Amel Sengal, BS, Carl E. Allen, MD PhD, Rikhia Chakraborty, PhD

Blood (2019) 134 (Supplement_1): 5399.

https://doi.org/10.1182/blood-2019-130588

Published: 2019

Journal Articles

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Gordon Ruan, MD, Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, N. Nora Bennani, MD, Karen Rech, MD, Jason Young, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 5895.

https://doi.org/10.1182/blood-2019-124891

Published: 2019

Journal Articles

Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition

Olive S. Eckstein, Johannes Visser, Carlos Rodriguez-Galindo, Carl E. Allen, the NACHO-LIBRE Study Group

Blood (2019) 133 (15): 1691–1694.

https://doi.org/10.1182/blood-2018-10-878363

Published: 2019

Includes: Supplemental data

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 406.

https://doi.org/10.1182/blood-2018-99-117577

Published: 2018

Journal Articles

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

Mateo Mejia Saldarriaga, MD, Amir Steinberg, MD, Adam F. Binder, MD

Blood (2018) 132 (Supplement 1): 5136.

https://doi.org/10.1182/blood-2018-99-112652

Published: 2018

Journal Articles

PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease

Frédéric Charlotte, MD, Fleur Cohen-Aubart, MD PhD, Levi-Dan Azoulay, MD, Jean Donadieu, MD PhD, Jean-François Emile, MD PhD, Zahir Amoura, MD, Julien Haroche

Blood (2018) 132 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2018-99-114031

Published: 2018

NARROW

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

BRAF V600E vs cell of origin: what governs LCH?

Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Erdheim-Chester disease

Langerhans cell histiocytosis

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

BRAF V600E-Positive Precursors As Molecular Markers of Bone Marrow Involvement in Pediatric Langerhans Cell Histiocytosis

Determining Resistance Mechanisms in BRAF- mutated Multiple Myeloma

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Liquid Biopsy Is Useful to Identify the Genetic Profile of NHL-B at Diagnosis in Different Histological Subtypes

Creating and Testing a CD207+ Langerhans Cell Histiocytosis-like Cell Line

Low-Dose BRAF-Inhibitors in the Treatment of Histiocytic Disorders with the BRAF-V600E Mutation

Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

A Case of CCDC6-RET Fusion Mutation in Adult Acute Lymphoblastic Leukemia (ALL), a Known Activating Mutation Unreported in ALL

PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only